What is Organigram Global Inc.'s (OGI) StockRank?

MoatMap's StockRank for Organigram Global Inc. (OGI) is 31/100, with a Sell signal. This is a composite score combining Quality (45), Value (48), and Momentum (28) factor ranks across MoatMap's 20,000+ stock universe.

Does Organigram Global Inc. have an economic moat?

Organigram Global Inc. (OGI) has a Quality factor score of 45/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Organigram Global Inc. a buy, hold, or sell?

MoatMap's current signal for Organigram Global Inc. (OGI) is Sell, based on a StockRank of 31/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Organigram Global Inc. in?

Organigram Global Inc. (OGI) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Canada).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

OGI

SELLREMOVE

Organigram Global Inc. · Healthcare · Canada · $138M · Avg Vol: $593K/d

StockRank

P/E (TTM)

—

ROE

-5.9%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Organigram is a Canadian cannabis producer. The industry is structurally broken, characterized by chronic oversupply, lack of pricing power, heavy regulatory burdens, and persistent cash burn. It fails every single quality lens.

COMPANY DESCRIPTION

Organigram Global Inc. (operating as Organigram Holdings) is a licensed producer of medical cannabis and cannabis-derived products, focusing on both the recreational and medical markets in Canada and internationally. The company differentiates itself through its indoor cultivation expertise, product innovation, and expanding distribution network, aiming to capture market share in the evolving cannabis industry.

FINANCIAL SUMMARY (USD)

Year	2021	2022	2024	2025	CAGR
Revenue	55.9M	102.9M	112.8M	182.9M	48.5%
EPS	-1.44	-0.13	-0.34	-0.14	—
Shares	74.7M	78.5M	108.6M	134.5M	+80.0%
Debt	4.2M	2.4M	3.1M	6.2M	13.8%
Equity	338.6M	358.6M	215.9M	246.4M	-10.1%
Op CF	-20.2M	-25.6M	2.7M	-5.4M	—
Inv CF	-81.2M	31.1M	-21.7M	-57.2M	—
Fin CF	123.1M	3.8M	76.1M	27.8M	—

PRICE (1Y)-13.9%

SMA 50SMA 200

$0.96

RSI (14)

23.9

52W High

$2.24

From 52W High

0.4%

SCORE BREAKDOWN

Quality

ROIC

-3.5%40.9

ROE

-5.9%38.6

GP/Assets

12.3%30.3

Op. Margin

-16.4%27.5

FCF/Assets

2.0%57.7

Piotroski

430.1

Int. Cover

—N/A

D/E Ratio

0.02x83.3

Current Ratio

2.82x51.0

Value

P/E (TTM)

—N/A

EV/EBITDA

89.5x6.3

P/FCF

12.1x76.9

P/B

0.7x91.7

P/S

0.7x88.3

Div Yield

—N/A

Momentum

52W High %

43%16.4

RS 6M

-58%18.3

SMA 50/200

0.80x14.5

EPS Rev 4W

0.0%49.3

EPS Rev 12W

—N/A

EPS Improve

+115%76.5

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$138M

P/E (Forward)

44.3x

Gross Margin

35.6%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OGI are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
OGI	Organigram Global Inc.(you)	$138M	31	SELL
ACB	Aurora Cannabis Inc.	$181M	30	SELL
CRDL.TO	Cardiol Therapeutics Inc.	$123M	22	SELL
NVRS.CN	Noveris Health Sciences Inc.	$64M	23	SELL
LEEF.CN	Leef Brands Inc.	$46M	29	SELL
WEED.TO	Canopy Growth Corporation	$501M	21	SELL
TLRY.TO	Tilray Brands, Inc.	$781M	29	SELL
HLS.TO	HLS Therapeutics Inc.	$100M	63	HOLD
DB.V	Decibel Cannabis Company Inc.	$50M	60	HOLD
OPTI.CN	Optimi Health Corp.	$25M	2	STRONG SELL

Peer medians: ROE -48.5% · P/E 14.3x · Gross margin 30.1%

Organigram Global Inc. (OGI) — Stock Score Summary

Organigram Global Inc. (OGI) has a MoatMap StockRank of 31/100 based on Quality (45/100), Value (48/100), and Momentum (28/100) factor scores. The current signal is SELL. Organigram is a Canadian cannabis producer. The industry is structurally broken, characterized by chronic oversupply, lack of pricing power, heavy regulatory burdens, and persistent cash burn. It fails every single quality lens.

Key Financial Metrics

Price	$0.96
Market Cap	$138M
P/E (Forward)	44.31
Price/Book	0.71
Return on Equity	-5.9%
Return on Invested Capital	-3.5%
Debt/Equity	1.93
Gross Margin	35.6%
Operating Margin	-16.4%
Revenue Growth	-8.9%
Free Cash Flow	$11M

Organigram Global Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (Canada).

Frequently Asked Questions

What is Organigram Global Inc.’s (OGI) StockRank?: MoatMap’s StockRank for Organigram Global Inc. (OGI) is 31/100, with a Sell signal. It is a composite of Quality (45), Value (48), and Momentum (28) factor ranks across MoatMap’s 20,000+ stock universe.
Does Organigram Global Inc. have an economic moat?: Organigram Global Inc. (OGI) has a Quality factor score of 45/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Organigram Global Inc. a buy, hold, or sell?: MoatMap’s current signal for Organigram Global Inc. (OGI) is Sell, based on a StockRank of 31/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Organigram Global Inc. in?: Organigram Global Inc. (OGI) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Canada).